Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Macrophage-stimulating protein (MSP)
- Target
- MSP
- Molecular classification
- Growth factor, Ligand, Serine protease family (but weak or non-active), Secreted protein
01
Overview
Macrophage-stimulating protein (MSP) is a secreted, disulfide-linked heterodimeric protein consisting of alpha and beta chains, structurally related to hepatocyte growth factor and plasminogen. Despite possessing a serine protease domain, MSP is thought to have little or no proteolytic activity. MSP is the endogenous ligand for the RON receptor tyrosine kinase, and its binding stimulates cellular processes such as motility, immune cell activation, and epithelial cell ciliary action, and it is involved in immunoregulatory and inflammatory responses. MSP plays disease roles in immunodeficiency, primary sclerosing cholangitis, and may contribute more broadly to immune and epithelial biology
- Other names
- Hepatocyte growth factor-like proteinHGFLHepatocyte growth factor-like protein alpha chainHepatocyte growth factor-like protein beta chainD3F15S2DNF15S2HGFLPNF15S2HLPMacrophage-stimulatory protein
02
Mechanism of action
Acts by binding and activating the RON (MST1R) receptor tyrosine kinase, leading to downstream signaling affecting cell migration, survival, and immune responses
03
Biological functions
Cell migrationSignal transduction (through receptor tyrosine kinase activation)Immune response modulationMacrophage activation/stimulationRegulation of ciliary movement in airway epithelium
04
Disease associations
ImmunodeficiencyCholestatic liver diseases (e.g., primary sclerosing cholangitis)Inflammatory diseasePotential involvement in cancer and additional immune dysregulation
05
Safety considerations
No direct therapeutic agents, so no known clinical safety concernstheoretical concerns would relate to modulation of immune function and cell migration (e.g., risk of immune dysregulation or tumor promotion if targeted)
06
Interacting drugs
None clearly established or approved as of now (Ligand; not known as current direct drug target)
07
Biomarkers
No established clinical biomarkers for patient selection or efficacy monitoringpotential as biomarker for certain immune or hepatic conditions remains largely investigational
Beyond the preview
Go deeper on Macrophage-stimulating protein (MSP).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Macrophage-stimulating protein (MSP).